NCT06227975

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

A Phase 1, Single-center, Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Celgene · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[14C]-BMS-986368	Specified dose on specified days

Timeline

• Start date: 2024-02-02
• Primary completion: 2024-04-03
• Completion: 2024-04-03
• First posted: 2024-01-29
• Last updated: 2024-05-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study